Progesterone Receptor Status and Clinical Outcome in Breast Cancer Patients with Estrogen Receptor-Positive Locoregional Recurrence. Issue 4 (July 2015)

• Record Type: Journal Article
• Authors: Bogina, Giuseppe; Lunardi, Gianluigi; Coati, Francesca; Zamboni, Giuseppe; Gori, Stefania; Bortesi, Laura; Marconi, Marcella; Cassandrini, Paola Agnese; Turazza, Monica; Cortesi, Laura; DeMatteis, Elisabetta; Ficarra, Guido; Ibrahim, Toni; Serra, Patrizia; Medri, Laura; Giraudi, Sara; Lambertini, Matteo; Carli, Franca; Foglietta, Jennifer; Sidoni, Angelo; Nunzi, Martina; Ficorella, Corrado; Diadema, Maria Rosaria; Del Mastro, Lucia
• Is Part Of: Tumori. Volume 101:Issue 4(2015)
• Page Start: 398
• Page End: 403
• Publication Date: 2015-07
• Subjects: Breast cancer -- Locoregional recurrence -- Metastasis -- Progesterone receptor; Cancer -- Periodicals; 616.994
• DOI: 10.5301/tj.5000323
• Languages: English
• ISSNs: 0300-8916

Abstract

Aims and background: The aim of this retrospective multicenter study was to evaluate the impact of progesterone receptor (PgR) loss on locoregional recurrence in patients with estrogen receptor (ER)-positive primary breast cancer and ER-positive locoregional recurrence. Patients and Methods: Eight Italian oncology centers collected data from consecutive patients with ER-positive breast cancer and a subsequent ER-positive locoregional recurrence. Results: Data were available for 265 patients diagnosed with breast cancer between 1990 and 2009. Median metastasis-free survival was 111 months in patients with PgR-positive primary tumors and locoregional recurrence (PgR pos ), 38 months in patients with PgR-negative primary tumors and locoregional recurrence (PgR neg ), and 63 months in patients with PgR-positive primary tumors and PgR-negative locoregional recurrence (PgR loss ). In multivariate analysis, PgR status was independently associated with metastasis-free survival, with a hazard ratio of 2.84 (95% CI 1.34-6.00) for PgR neg compared with PgR pos, and 2.93 (95% CI: 1.51-5.70) for PgR loss compared with PgR pos . Conclusions: PgR absence was found to be a negative prognostic factor in breast cancer patients with ER-positive locoregional recurrence. Thus, PgR status could be a biological marker in ER-positive recurrent breast cancer.